Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, District of Columbia 20007, USA.
Curr Opin Oncol. 2010 May;22(3):263-7. doi: 10.1097/CCO.0b013e3283380939.
Prostate cancer remains a medical dilemma and a major cause of morbidity and mortality in many western countries. It represents the most common cancer in US men, with an estimated 192 280 new cases diagnosed in 2009. The median survival for men with metastatic castrate-resistant prostate cancer is 1-2 years, with improvements in survival seen primarily with docetaxel-based therapies. The purpose of this article is to discuss developments of novel agents in the field of metastatic castration-resistant prostate cancer (CRPC), including new cytotoxic agents, immune-based therapies, circulating tumor markers and targeting agents.
During this past year, several promising approaches yielded disappointing results in the phase III setting (GVAX); nonetheless, expectations for other agents (Abiraterone, MDV3100, Zibotentan, immunotherapy agents) still remain high.
Systemic therapy options are limited in CRPC and survival benefit remains to be seen with the new therapies. Circulating tumor cells continue to provide important prognostic information and will likely become an important aspect of future clinical decision-making.
前列腺癌仍然是一个医学难题，也是许多西方国家发病率和死亡率的主要原因。它是美国男性最常见的癌症，据估计 2009 年有 192280 例新发病例。转移性去势抵抗性前列腺癌患者的中位生存期为 1-2 年，主要通过多西紫杉醇为基础的治疗来提高生存率。本文旨在讨论转移性去势抵抗性前列腺癌（CRPC）领域新型药物的发展，包括新的细胞毒性药物、免疫治疗、循环肿瘤标志物和靶向药物。
在过去的一年中，几项有前途的方法在 III 期研究（GVAX）中结果令人失望；尽管如此，人们对其他药物（阿比特龙、MDV3100、Zibotentan、免疫治疗药物）仍抱有很高的期望。
CRPC 的系统治疗选择有限，新的治疗方法仍有待观察生存获益。循环肿瘤细胞继续提供重要的预后信息，并可能成为未来临床决策的一个重要方面。
